Tech Company Financing Transactions
Trigemina Funding Round
Trigemina, based in Mountain View, secured $4.5 million from Aurus Bios Fund and private investors.
Transaction Overview
Company Name
Announced On
6/20/2013
Transaction Type
Venture Equity
Amount
$4,500,000
Round
Series A
Investors
Aurus Bios Fund (Lead Investor)
Proceeds Purpose
Proceeds for the Series A-1 round will be used to fund the completion of the Phase II TRIG-05 clinical trial evaluating the Company's lead drug candidate, TI-001, an intranasal oxytocin therapy, for the treatment of chronic migraine.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
809B Cuesta Dr. 109
Mountain View, CA 94040
USA
Mountain View, CA 94040
USA
Phone
Website
Email Address
Overview
Trigemina, Inc. exploits a newly discovered pathway for targeting the central nervous system, enabling vast new opportunities for treating acute and chronic pain.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
William St. John
Chief Financial Officer
Michael Leonard
Chief Medical Officer
Shashidhar Kori
Chief Scientific Officer
David Yeomans
VP - Finance
Kayla Danna
Browse more venture capital transactions:
Prev: 6/20/2013: Nano-Meta Technologies venture capital transaction
Next: 6/20/2013: Apex Learning venture capital transaction
Share this article
About Our VC Transactions Data
We document tech company VC transactions. All VC database entries reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs